These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 2889032)

  • 41. 11 beta-Hydroxysteroid dehydrogenase and enzyme-mediated receptor protection: life after liquorice?
    Walker BR; Edwards CR
    Clin Endocrinol (Oxf); 1991 Oct; 35(4):281-9. PubMed ID: 1661215
    [No Abstract]   [Full Text] [Related]  

  • 42. Licorice, computer-based analyses of dehydrogenase sequences, and the regulation of steroid and prostaglandin action.
    Baker ME; Fanestil DD
    Mol Cell Endocrinol; 1991 Jun; 78(1-2):C99-102. PubMed ID: 1834493
    [No Abstract]   [Full Text] [Related]  

  • 43. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic analysis of 11 beta-hydroxysteroid dehydrogenase.
    White PC; Obeid J; Agarwal AK; Tannin GM; Nikkila H
    Steroids; 1994 Feb; 59(2):111-5. PubMed ID: 8191538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action.
    Whorwood CB; Sheppard MC; Stewart PM
    Endocrinology; 1993 Jun; 132(6):2287-92. PubMed ID: 8504732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
    Stewart PM; Walker BR; Holder G; O'Halloran D; Shackleton CH
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3617-20. PubMed ID: 8530609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low doses of liquorice can induce hypertension encephalopathy.
    Russo S; Mastropasqua M; Mosetti MA; Persegani C; Paggi A
    Am J Nephrol; 2000; 20(2):145-8. PubMed ID: 10773616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform.
    Stewart PM; Murry BA; Mason JI
    J Clin Endocrinol Metab; 1994 Aug; 79(2):480-4. PubMed ID: 8045966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isozymes of 11 beta-hydroxysteroid dehydrogenase: which enzyme endows mineralocorticoid specificity?
    Krozowski ZS; Provencher PH; Smith RE; Obeyesekere VR; Mercer WR; Albiston AL
    Steroids; 1994 Feb; 59(2):116-20. PubMed ID: 8191539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cortisol and hypertension: what was not so apparent about "apparent mineralocorticoid excess".
    Edwards C; Walker B
    J Lab Clin Med; 1993 Dec; 122(6):632-5. PubMed ID: 8245680
    [No Abstract]   [Full Text] [Related]  

  • 51. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Agarwal AK
    Endocr Rev; 1997 Feb; 18(1):135-56. PubMed ID: 9034789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
    Walker BR
    Steroids; 1994 Feb; 59(2):84-9. PubMed ID: 8191553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor.
    Edwards CR; Stewart PM; Burt D; Brett L; McIntyre MA; Sutanto WS; de Kloet ER; Monder C
    Lancet; 1988 Oct; 2(8618):986-9. PubMed ID: 2902493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 11 beta-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial Hypertension. Diagnosis and therapeutic approach in two young brothers.
    Gourmelen M; Saint-Jacques I; Morineau G; Soliman H; Julien R; Fiet J
    Eur J Endocrinol; 1996 Aug; 135(2):238-44. PubMed ID: 8810740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.
    Speiser PW; Riddick LM; Martin K; New MI
    Metabolism; 1993 Jul; 42(7):843-5. PubMed ID: 8393954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
    Mune T; Rogerson FM; Nikkilä H; Agarwal AK; White PC
    Nat Genet; 1995 Aug; 10(4):394-9. PubMed ID: 7670488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.
    Quinkler M; Meyer B; Oelkers W; Diederich S
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3767-72. PubMed ID: 12915667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone--in vivo and in vitro studies].
    Ojima M; Satoh K; Gomibuchi T; Itoh N; Kin S; Fukuchi S; Miyachi Y
    Nihon Naibunpi Gakkai Zasshi; 1990 May; 66(5):584-96. PubMed ID: 2384181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 11 beta-Hydroxysteroid dehydrogenase.
    Stewart PM
    Baillieres Clin Endocrinol Metab; 1994 Apr; 8(2):357-78. PubMed ID: 8092977
    [No Abstract]   [Full Text] [Related]  

  • 60. Apparent mineralocorticoid excess type II.
    Mantero F; Tedde R; Opocher G; Dessi Fulgheri P; Arnaldi G; Ulick S
    Steroids; 1994 Feb; 59(2):80-3. PubMed ID: 8191552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.